4/23/2019 8:35:10 AM
Akari Therapeutics Announces Positive Initial Phase II Clinical Data In Orphan Skin Disease Bullous Pemphigoid
11/15/2018 6:51:26 AM
Akari Therapeutics Q3 Net Loss $3.6 Mln Vs Net Loss $10.4 Mln Last Year
9/27/2018 7:10:02 AM
Akari Therapeutics Q2 Net Loss $8.0 Mln Vs Loss Of $0.3 Mln Last Year
9/27/2018 7:07:27 AM
Akari Therapeutics Enters Securities Purchase Agreement For Up To $20 Mln With Aspire Capital Fund, LLC
9/12/2018 7:11:43 AM
Akari Reports New Preclinical Rheumatoid Arthritis Data And New Clinical Data In Patients With Bullous Pemphigoid
8/17/2018 7:03:49 AM
Akari Therapeutics Q1 Net Loss $1.3 Mln Vs Loss Of $12.6 Mln Last Year
3/21/2018 7:05:40 AM
Akari Therapeutics Q4 Net Loss Widens To $9.3 Mln From $8.3 Mln Last Year
2/6/2018 7:11:02 AM
Akari Therapeutics Announces Completion Of Phase II COBALT Trial Of Coversin In Patients With PNH
5/12/2017 6:47:50 AM
William Blair Downgrades Akari Therapeutics Plc (AKTX) To Market Perform From Outperform
4/6/2017 7:11:21 AM
William Blair Initiates Akari Therapeutics Plc (AKTX) At Outperform